Overview

Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation

Status:
Completed
Trial end date:
2019-08-12
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, open-label, blinded end-point evaluation trial. The patient population consists of patients on hemodialysis who have atrial fibrillation (AF) and end-stage renal disease (ESRD) .
Phase:
Phase 4
Details
Lead Sponsor:
Christopher Granger
Christopher Granger, MD
Collaborator:
Bristol-Myers Squibb
Treatments:
Apixaban
Warfarin